After Blueprint's takeover comes Cogent's big test
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
Arvinas and 3SBio hope to do better
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
EHA 2025 – ELVN-001 enlivens investors
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
